Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Characterization of the Genetic Landscape of High Grade B-cell Lymphoma to Elucidate Molecular Determinants and Identify Therapeutic Targets

EF 2019-20

Résumé
"Lymphoma is the 5th most common form of cancer in North America, with ~130,000 new cases each year in the US. High grade B-cell lymphoma (HGBL) is a particularly aggressive form of lymphoma with low survival rates. Efforts to cure HGBL have been limited to using more intense forms of chemotherapy. This strategy has been largely unsuccessful, curing only 20-40% of patients. Additionally, a consequence of this strategy is that intensified chemotherapy leads to increased toxicity, resulting in frequent hospitalizations, which comes at a significant financial cost. Advances in treatment for HGBL is limited by our poor understanding of the underlying biology of this disease. Additionally, HGBL is distinguished from other types of lymphoma using methods established decades ago. These methods fail to identify the true complexity of the disease. Advances in technology have identified that subtypes of cancer are much more complex than initially thought, with no two cancers being completely identical. This has led to the establishment of ""personalized medicine"", where patients receive treatment specifically aimed at targets unique to their cancer. Through revealing the molecular basis of HGBL, this project aims to identify, prior to treatment, the 60-80% of patients in whom chemotherapy will be ineffective. Within this group, we aim to identify therapeutic targets that are specific to these patients, as well as therapeutic targets that are shared with other forms of lymphoma. Precision medicine is the path to improving the dismal outcomes of patients with HGBL - particularly in those who do not benefit from chemotherapy. This research will ultimately reshape how we define HGBL and guide the development of new drugs and treatment strategies."
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428760
Name
Collinge Brett J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of the Genetic Landscape of High Grade B-cell Lymphoma to Elucidate Molecular Determinants and Identify Therapeutic Targets
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Genomics; Lymphoma; Precision Medicine
Abstract
"Lymphoma is the 5th most common form of cancer in North America, with ~130,000 new cases each year in the US. High grade B-cell lymphoma (HGBL) is a particularly aggressive form of lymphoma with low survival rates. Efforts to cure HGBL have been limited to using more intense forms of chemotherapy. This strategy has been largely unsuccessful, curing only 20-40% of patients. Additionally, a consequence of this strategy is that intensified chemotherapy leads to increased toxicity, resulting in frequent hospitalizations, which comes at a significant financial cost. Advances in treatment for HGBL is limited by our poor understanding of the underlying biology of this disease. Additionally, HGBL is distinguished from other types of lymphoma using methods established decades ago. These methods fail to identify the true complexity of the disease. Advances in technology have identified that subtypes of cancer are much more complex than initially thought, with no two cancers being completely identical. This has led to the establishment of ""personalized medicine"", where patients receive treatment specifically aimed at targets unique to their cancer. Through revealing the molecular basis of HGBL, this project aims to identify, prior to treatment, the 60-80% of patients in whom chemotherapy will be ineffective. Within this group, we aim to identify therapeutic targets that are specific to these patients, as well as therapeutic targets that are shared with other forms of lymphoma. Precision medicine is the path to improving the dismal outcomes of patients with HGBL - particularly in those who do not benefit from chemotherapy. This research will ultimately reshape how we define HGBL and guide the development of new drugs and treatment strategies."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Collinge, Brett J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~